Navigation Links
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
Date:11/8/2007

Fong will lead sales and marketing of CTI products

SEATTLE, Nov. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that Jim Fong has been appointed the company's Vice President, Commercial Operations. Fong joins CTI with more than 20 years of sales and marketing experience. Most recently, Fong was National Sales Director at CV Therapeutics (CVT) in Palo Alto, California, where he led the launch of Ranexa(R) for chronic angina. CTI recently agreed to acquire the drug ZEVALIN(R) from Biogen Idec for development, marketing, and sale in the United States. Closing of the acquisition, which remains subject to closing conditions including obtaining certain third party consents, is expected in mid-November.

"Jim did a great job at the launch of Ranexa and streamlining CVT's commercial operations. With his prior expertise in marketing and sales, and the launch of a novel blockbuster anti-cancer agent Camptosar(R), Jim has the ideal credentials to positively impact the ZEVALIN relaunch while optimizing the positioning of our future oncology products like pixantrone," noted James A. Bianco, M.D., President and CEO of CTI.

Fong, who will report directly to Dr. Bianco, will be in charge of directing the sales and promotion of CTI products at the national and international levels. This will include product positioning, promotional programs, reimbursement strategies, and development and training of a national sales force.

"I am very pleased to join the CTI team and help re-establish a strong sales and marketing presence for the company," said Fong. "ZEVALIN is a great product and CTI is on an upward growth path with multiple opportunities for product launches in the coming years."

At CVT, Fong managed a sales team of more than 200 people, including business managers, marketing and sales operations, and the sales training department. Prior to CVT, Fong directed several sales teams and als
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. WorldHeart Appoints David Pellone Chief Financial Officer
8. Novo Nordisk Appoints New Leader of North American Business
9. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
10. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
11. Resonant Medical Appoints New Vice President of Global Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August is Children’s Eye Health and ... about eye health and safety for their children and ... condition that must be checked for, according to Sharon ... Water radio show, is pediatric dry eye. With computer ... eye is becoming a very real concern to ophthalmologists. ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Biosimilars, ... that are approved through an abbreviated process, could ... issue of Atlantic Information Services, Inc.’s (AIS) Specialty ... this segment, including the Food and Drug Administration’s ... first step towards approval. , Drugmaker Sandoz said ...
(Date:8/20/2014)... August 20, 2014 Ticketability.com ... public at fair prices. The well-known medium has been ... is now touring in 19 cities, with tickets becoming ... television personality will visit are Albany, Baltimore, Trenton, Erie, ... Albuquerque, Beverly Hills and San Diego. The medium’s fans ...
(Date:8/20/2014)... often have difficulty falling asleep and staying asleep, and ... individuals with Alzheimer,s disease, this common and troubling symptom ... to nighttime confusion and wandering. , Now, a study ... (BIDMC) and the University of Toronto/Sunnybrook Health Sciences Center ... Reported online today in the journal Brain , ...
(Date:8/20/2014)... At this moment, Ebola is causing horrific, ... the root cause of the virus and other problems Africans ... nonprofit organization Books For Africa to provide copies of his ... Live the Life of Their Dreams, to those who could ... with the tools they need to make the leap to ...
Breaking Medicine News(10 mins):Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 3
... heart attacks, strokes among those without established heart ... An analysis of studies supports a growing belief ... be expanded to include healthy people without established ... 10 trials involving more than 70,000 participants found ...
... Services to Focus on the Delivery of Early Stage Services -, ... July 1 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: ... global life sciences markets, today announced that it has completed the ... Under the terms of the agreement, INC Research, a leading global ...
... new treatments eliminate risks of traditional procedures , , ROSEMONT, ... respond successfully to initial treatment may have a second chance at ... area, according to a study published in the July 2009 issue ... Academy of Orthopaedic Surgeons (JAAOS). ...
... Netherlands: Survivors of childhood cancer run particular risks ... 25th annual conference of the European Society of ... July). Dr. Sharon Lie Fong, of the Department ... Centre, Rotterdam, The Netherlands, said that, although such ...
... , AstraZeneca Patent Shown to be Invalid Based on New ... , , NEW YORK, July 1 Article ... validity of AstraZeneca,s Crestor U.S. drug patent, in closing out ... premier validity evidence which can show the Crestor patent to ...
... ... Center Leverages Fusionfx Solution Suite to Improve Patient Experience , ... Scottsdale, AZ (Vocus) June ... a nationally recognized non-profit provider of integrated health services, has chosen the Fusionfx ...
Cached Medicine News:Health News:Study Supports Wider Use of Statins 2Health News:Study Supports Wider Use of Statins 3Health News:MDS Inc. Completes Divestiture of MDS Pharma Services Phase II-IV Operations 2Health News:Emerging Techniques Put a New Twist on Ankle Repair 2Health News:Emerging Techniques Put a New Twist on Ankle Repair 3Health News:Cancer survivors at greater risk of birth complications; special monitoring needed 2Health News:Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 2Health News:Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 3Health News:Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 4Health News:Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 2Health News:Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 3
(Date:8/19/2014)... KIRKLAND, Wash. , Aug. 19, 2014 ... solutions, will be exhibiting at the 2014 NPPA Summer ... The company will be showcasing its 340B software products ... leader in 340B splitting solutions, supplying over 400 customers ... a range of 340B solutions including its latest solution, ...
(Date:8/19/2014)... YORK , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage ... will present a scientific poster describing an innovative diagnostic ... SPEC 2014: Shedding New Light on Disease (SPEC) conference ... Dr. Treado,s poster entitled, "Development of in vitro ... Imaging" will be discussed during the conference poster session ...
(Date:8/19/2014)... , Aug. 19, 2014  Tokyo-based Atonarp Inc. ... funding round led by Walden Riverwood Ventures with ... development of Atonarp,s Smart Spectrometer technology platform, which ... company has targeted the oil & gas and ... "We are excited to partner with Atonarp in ...
Breaking Medicine Technology:Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2
... China Botanic Pharmaceutical Inc. (AMEX: CBP ) ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ... the Company,s new Chief Financial Officer ("CFO") on December ... over 10 years with key positions in finance, audit, ...
... Calif. and LUXEMBOURG, Dec. 16, 2010 WaferGen Biosystems, ... leading developer of state-of-the-art genomic analysis systems, and the ... to establish a strategic relationship that will expand the ... Europe and advance personalized medicine.   The ...
Cached Medicine Technology:China Botanic Appoints David Dong as New Chief Financial Officer 2China Botanic Appoints David Dong as New Chief Financial Officer 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 2WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 4WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 5
Inquire...
Inquire...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: